Editorial
 Noteworthy Performance By India Inc   
 Wednesday, August 21, 2019 
 In spite of several headwinds such as increased competition, US FDA’s warning letters on quality issues, price cuts and limited success from R&D activities, the top Indian pharmaceutical companies have been able to register a decent growth in sales 
  Past Editorial...  
Pharmaxil_Export Awards_2019_540x72
TODAY'S NEWS
17:00  [IST]Centinel Spine reports first use of expanded prodisc C family of devices in US clinical study
16:00  [IST]Satsuma Pharma begins phase 3 EMERGE trial of STS101 to treat migraine
15:00  [IST]Chrysalis BioTherapeutics'TP508 to treat ARS gets US FDA & EMA orphan drug status
14:00  [IST]Retrophin's phase 3 FORT study of fosmetpantotenate in patients with PKAN fails to meet primary endpoint
13:00  [IST]Themis Bioscience inks research collaboration with MSD to develop vaccine candidates
12:00  [IST]Amgen, Allergan report positive results from comparative study of ABP 798, biosimilar candidate to Rituxan to treat patients with CD20-positive B-cell NHL
more news >>
TOP NEWS
08:00  [IST]PNB Vesper receives DCGI nod for 2 molecules to conduct phase 1/2a human studies
08:00  [IST]Health ministry to mandate medical device import licence holders towards SUSAR reporting
08:00  [IST]National Digital Health Blueprint could boost IoT based solutions for primary care in remote locations
08:00  [IST]Regulators need to curb unethical practices in human clinical trials: Prof Gagandeep Kang
08:00  [IST]GE Healthcare seeks solutions from start-ups through its Edison platform to provide cash in grant of US$ 10,000
08:00  [IST]DCGI sub-committee drafts document guidance on formulation development as per WHO guidelines
more news >>
YESTERDAY'S NEWS
18:00  [IST]Aimmune begins patient enrollment in phase 2 trial of AR201 for egg allergy treatment
17:00  [IST]NIH funds genetic counselling resource ahead of million-person sequencing effort
16:30  [IST]CRSA India meet on Aug 24 to usher in advancements in robotic surgery with participation of 250 surgeons
16:10  [IST]Sparsh Hospital sets up osteoporosis clinic to address rising incidence of osteoporosis
16:00  [IST]Innovent, Lilly ink licensing pact to develop & commercialize new diabetes medicine, OXM3 in China
14:10  [IST]US FDA issues 2 observations for Granules India's US facility
more news >>
INTERVIEW  
Advanced flooring, integral part of pharma & healthcare infrastructure
Agradeep Mondal, Director Sales, Interface South Asia115398Agradeep
Past Interviews...
 
  What's New?  
 
Opinion Poll
 
 
Is the DoP's recent amendment to Para 32 of DPCO to provide 5-year price control exemption to patented innovative & rare diseases drugs a right move to increase accessibility ?
 
 
 
   
 
  Corporate
Pharma Stocks
Executive Diary
Pharma People
Product Launches
  Special Features
Features
  Chronicle Pharmabiz Specials
Forthcoming
  Past
 
  Forthcoming Events
International
  Domestic
 
TENDERS & PROJECTS
Tenders & Enquiries
Pharma Projects
CORPORATE
Company Profile
Corporate Results
Corporate X-ray
Pharmabiz Studies of Top Companies
US FDA UPDATE
US FDA: ANDA
US FDA: Warnings
US FDA: Approved NMEs
US FDA: New Approvals
EXPORT & IMPORT
Drug Export Procedures
Drug Units With WHO GMP Certification
Pharma Export Data
Import Reg. Update
PHARMA LAWS & DOCUMENTS
Notifications
Pharma Regulations
Patent Laws and Amendments
Patent Scan
Documents
New Drug Approvals
Notified Prices
LIST OF LABS & GOVT. BODIES
Govt Recognised In-House R&D Units
AICTE Boards & Committees
List of Indian CROs
List of CROs (International)
Govt & approved labs of India
List of State Drugs Controllers
 
 
Pharma_BPP_150x60
CPhI_Mea_2019_ 150x60
India_Lab_Expro_150-x-60
Pharmatech-Expo-2019-Pharmabiz
CP: HI_Korea_2019_150x60
Medical Device
CPhI_Korea_2019_150x60
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |